12
Feb
2019
The Immune Sequencing Frontier (Take 2): Harlan and Chad Robins on The Long Run
Today’s guests on The Long Run are Harlan and Chad Robins. They are brothers and co-founders of Seattle-based Adaptive Biotechnologies. Chad is the CEO, and Harlan is the head of innovation. Harlan is also a faculty member at the Fred Hutchinson Cancer Research Center just down the street from Adaptive. Senior people in pharma R&D are quite familiar with Adaptive....Read More 
Share:
8
Feb
2019
Azar Angles for a Deal Pharma Can Live With, Macrogenics’ Big Break, & Sanofi Scraps 38 R&D Programs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
7
Feb
2019
Meet the Kilimanjaro Climb to Fight Cancer Team
The Kilimanjaro Climb to Fight Cancer team is ready to go. We have a full group of 28 biotech executives and investors – 14 women and 14 men – committed to climbing the highest peak in Africa this July. Working together, we’re raising $1 million for cancer research at Fred Hutch. With five months to go, we are about one-fourth...Read More
Share:
6
Feb
2019
Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle
We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment – these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer...Read More
Share:
30
Jan
2019
Finding a Way in Genomic Diagnostics: Bonnie Anderson of Veracyte on The Long Run
Bonnie Anderson is today’s guest on The Long Run. Bonnie is the CEO of Veracyte. It’s a genomic diagnostics company in South San Francisco. The company markets a line of tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte got started in 2008. Bonnie, as co-founder and CEO, was recruited by Kleiner Perkins Caufield & Byers and a...Read More
Share:
25
Jan
2019
Genentech CEO in, Editas CEO Out, & the Shutdown IPO?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
18
Jan
2019
House Dems Hunt Pharma Big Game, Shutdown Ripples, & JPM Reflections
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Jan
2019
Big Money For Glaring Global Health Needs: George Scangos on The Long Run
Today’s guest on The Long Run is George Scangos. Scangos is the CEO of San Francisco-based Vir Biotechnology. He’s best known for his last job as the CEO of Biogen, one of the industry’s biggest companies. He left that high-profile perch a little more than two years ago. Like many big company veterans, he heard the siren song to join...Read More
Share:
11
Jan
2019
Lilly Buys Loxo, Baselga Resurfaces, and Bluebird’s Gene Therapy Payment Plan
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Jan
2019
Genentech & Adaptive’s TCR Strategy, Arch’s New Cell Therapy Co, & Esperion’s Rich EU Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Jan
2019
Schrodinger Gets $85M for Computational Drug Discovery. Q&A with CEO Ramy Farid
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
4
Jan
2019
BMS-Celgene MegaMerger, Verily Pockets $1B, and AbbVie’s Wager on CD39
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
3
Jan
2019
Medicare’s CAR (-T) Wreck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
2
Jan
2019
From Merck Fast Track to Computer Chem Frontier: Karen Akinsanya on The Long Run
Today’s guest on The Long Run is Karen Akinsanya. Karen is the chief biomedical scientist at Schrodinger. The New York-based company is a leader in computational chemistry for drug discovery. The company is privately held, and not a household name. But some wealthy and powerful people know it well. Schrodinger counts Bill Gates and David E. Shaw, the hedge fund...Read More
Share:
2
Jan
2019
Hurricane Lantus Is Changing the Drug Pricing Dynamic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Dec
2018
Messenger RNA Therapies That You May Not Have Heard Of: Ron Renaud on The Long Run
Today’s guest on The Long Run is Ron Renaud. Ron is the CEO of Lexington, Mass.-based Translate Bio. The company is working on messenger RNA therapies. You may have heard about this technology. mRNA molecules provide genetic instructions for making proteins. The idea is to restore functional proteins that, for one reason or another, have gone awry in a disease...Read More
Share:
21
Dec
2018
Abernethy Goes to FDA, Relay’s Monster Round, & Gilead’s Boston Shopping Spree
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
20
Dec
2018
Relay Therapeutics Hauls in $400M to Push Frontier in Computational Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Dec
2018
Versant Ventures Reloads with $700M for Early-Stage Biotech
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
14
Dec
2018
Allen’s $125M Bet on Immunology, Gilead’s New CEO, & Insulin Price-Gouging Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: